- Proxima | Specialist Procurement Supply Chain Consultants
We are Proxima, a global procurement and supply chain consultancy that is part of the Bain procurement ecosystem We work alongside some of the world’s largest and most successful businesses to help them spend their money wisely, solving cost, capability, and sustainability challenges
- AI biotech Proxima raises $80M from DCVC and NVentures for molecular . . .
New York-based biotech startup Proxima has emerged from stealth with $80 million seed funding to reshape how medicines influence cells
- Proxima Raises $80 Million Led by DCVC to Power the Next . . . - BioSpace
NEW YORK BOSTON-- (BUSINESS WIRE)-- #AI -- Proxima (formerly VantAI), the AI-native biotech company pioneering the next generation of AI-driven drug discovery for proximity therapeutics, today announced an oversubscribed $80M seed financing The round was led by DCVC, with participation from NVentures (NVIDIA’s venture capital arm), Braidwell, Roivant, AIX Ventures, Yosemite, Magnetic
- Proxima CRO
About Proxima Our team of Clinical, Regulatory, and Quality experts have led Proxima to the forefront of the healthcare industry We continuously meet milestones, stay ahead of schedule, and ensure our clients overcome industry hurdles
- Proxima raises $80 million for AI drug discovery from DCVC, Nvidia - MSN
Proxima, a biotech startup using artificial intelligence to design drugs that control protein interactions, raised $80 million in seed funding, which will help it collect better data and
- Proxima Raises $80 Million to Advance AI-Driven Proximity-Based Drug . . .
BOSTON, Mass — Proxima, an AI-native biotechnology company focused on proximity-based medicines, said it has raised $80 million in an oversubscribed seed financing round to advance a new generation of AI-driven drug discovery
- Drug Discovery Firm Proxima Raises $80M in Seed Funding
NEW YORK — Drug discovery firm Proxima said on Tuesday that it has raised $80 million through an oversubscribed seed financing round The round was led by DCVC and included NVentures, Braidwell, Roivant, AIX Ventures, Yosemite, Magnetic Ventures, Alexandria Venture Investments, and Modi Ventures Proxima — formerly VantAI — is a Roivant subsidiary that is using AI to discover and develop
- Proxima lands $80m to make protein interactions programmable
AI-native biotech Proxima has raised $80 million in an oversubscribed seed round to advance new medicines designed to control how proteins interact with one another Previously known as VantAI, the company has rebranded as Proxima to reflect its focus on “proximity modulation” – a therapeutic strategy designed to influence which proteins come into contact, for how long, and under what
|